Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LivaNova PLCLIVN · Entity 507 | President, Cardiopulmonary | March 30, 2026 | April 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LivaNova PLC
Report date March 30, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,755 |
Ending reported balance
After 2026-03-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-30 · Exercise / conversion · Acquired 3,184 · Balance 12,125 F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Row 2 · 2026-03-30 · Tax withholding · Disposed 1,370 · Balance 10,755 F2: Shares withheld to satisfy tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-30 · Exercise / conversion · Disposed 171 · Balance 0 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F4: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 325 |
Reported balance
After 2026-03-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-30 · Exercise / conversion · Disposed 325 · Balance 325 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F5: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,117 |
Reported balance
After 2026-03-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-30 · Exercise / conversion · Disposed 558 · Balance 1,117 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F6: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,258 |
Reported balance
After 2026-03-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-30 · Exercise / conversion · Disposed 2,130 · Balance 4,258 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F7: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 219 |
Reported balance
Holding disclosure · report date 2026-03-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 219 |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value.
F2: Shares withheld to satisfy tax liability.
F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement.
F4: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement.
F5: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.
F6: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.
F7: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 2,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · derivative · entry 7 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,258 Underlying: Ordinary Shares · 2,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F7 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. F7 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 558 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · derivative · entry 6 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,117 Underlying: Ordinary Shares · 558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F6 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F6 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 325 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · derivative · entry 5 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Ordinary Shares · 325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F5 · derivative.exercise_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F5 · derivative.expiration_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 171 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F4 · derivative.exercise_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F4 · derivative.expiration_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 1,370 | $61.27 | $83,939.90 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,755 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 3,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000026 · wk-form4_1775078421.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 17:25 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionStock Appreciation Rights · Derivative | 2,140 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001639691-26-000015 · wk-form4_1773437128.xml · derivative · entry 5 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,140 shares Expires 2026-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reporting person was granted SARs on March 11, 2016 that vested in four equal annual installments beginning March 11, 2017 under the LivaNova PLC 2015 Incentive Award Plan and were automatically exercised upon their March 11, 2026 expiration date. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 17:25 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 69 | $62.26 | $4,295.94 |
DisclosureSEC source: 0001639691-26-000015 · wk-form4_1773437128.xml · nonDerivative · entry 3 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,941 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 17:25 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 1,980 | $62.26 | $123,274.80 |
DisclosureSEC source: 0001639691-26-000015 · wk-form4_1773437128.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,010 F1 · shares: Shares withheld for stock appreciation right ("SAR") base price settlement. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 17:25 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 2,140 | $57.60 | $123,264.00 |
DisclosureSEC source: 0001639691-26-000015 · wk-form4_1773437128.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:06 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 967 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000163 · wk-form4_1766005586.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the "Plan") and the award agreement. F4 · derivative.exercise_date: On December 15, 2023, reporting person was granted RSUs subject to a two-year vesting schedule, the final vesting for which occurred on December 15, 2025. The RSUs were subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. F4 · derivative.expiration_date: On December 15, 2023, reporting person was granted RSUs subject to a two-year vesting schedule, the final vesting for which occurred on December 15, 2025. The RSUs were subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:06 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 416 | $63.06 | $26,232.96 |
DisclosureSEC source: 0001639691-25-000163 · wk-form4_1766005586.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,850 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:06 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 967 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000163 · wk-form4_1766005586.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units ("RSUs") settled in ordinary shares of LivaNova PLC (the "Company"), GBP 1.00 par value. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 16:05 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 643 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000135 · wk-form4_1758139532.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,932 Underlying: Ordinary Shares · 643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the "Plan") and the award agreement. F4 · derivative.exercise_date: On September 15, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments. The first vesting occurred on September 15, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. F4 · derivative.expiration_date: On September 15, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments. The first vesting occurred on September 15, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 16:05 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 277 | $55.43 | $15,354.11 |
DisclosureSEC source: 0001639691-25-000135 · wk-form4_1758139532.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,299 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 16:05 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 643 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000135 · wk-form4_1758139532.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units ("RSUs") settled in ordinary shares of LivaNova PLC (the "Company"), GBP 1.00 par value. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | GrantStock Appreciation Rights · Derivative | 13,986 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 12 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,986 Underlying: Ordinary Shares · 13,986 shares Expires 2035-03-30 F13 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 6,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 11 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,388 Underlying: Ordinary Shares · 6,388 shares Expires not disclosed F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F12 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F12 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 3,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 10 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194 Underlying: Ordinary Shares · 3,194 shares Expires not disclosed F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F11 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F11 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 3,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 9 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194 Underlying: Ordinary Shares · 3,194 shares Expires not disclosed F9 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F10 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F10 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 6,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 8 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,388 Underlying: Ordinary Shares · 6,388 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F8 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F8 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 559 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 7 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675 Underlying: Ordinary Shares · 559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F7 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F7 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 325 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 6 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650 Underlying: Ordinary Shares · 325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F6 · derivative.exercise_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F6 · derivative.expiration_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 5 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171 Underlying: Ordinary Shares · 172 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F4 · derivative.exercise_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F4 · derivative.expiration_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F3 · derivative.exercise_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F3 · derivative.expiration_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 542 | $39.13 | $21,208.46 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,933 Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:00 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 1,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000023 · wk-form4_1743555619.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 17:23 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 967 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000150 · wk-form4_1734474176.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967 Underlying: Ordinary Shares · 967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the LivaNova PLC 2022 Incentive Award Plan (the "Plan") and the award agreement. F4 · derivative.exercise_date: On December 15, 2023, reporting person was granted RSUs subject to a two-year vesting schedule, the first vesting for which occurred on December 15, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. F4 · derivative.expiration_date: On December 15, 2023, reporting person was granted RSUs subject to a two-year vesting schedule, the first vesting for which occurred on December 15, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 17:23 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 416 | $51.50 | $21,424.00 |
DisclosureSEC source: 0001639691-24-000150 · wk-form4_1734474176.xml · nonDerivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,218 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 17:23 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 967 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000150 · wk-form4_1734474176.xml · nonDerivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units ("RSUs") settled in ordinary shares of LivaNova PLC (the "Company"), GBP 1.00 par value. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 16:05 UTC | LivaNova PLC LIVN · Entity 507 | GrantStock Appreciation Rights · Derivative | 5,885 | $0.00 Strike: $48.53 | $0.00 |
DisclosureSEC source: 0001639691-24-000123 · wk-form4_1726603520.xml · derivative · entry 5 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,885 Underlying: Ordinary Shares · 5,885 shares Expires 2034-09-15 F7 · derivative.exercise_date: On September 15, 2024, reporting person was granted stock appreciation rights ("SARs") subject to a four-year vesting in equal annual installments, the first vesting occurring on September 15, 2025. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 16:05 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000123 · wk-form4_1726603520.xml · derivative · entry 4 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Underlying: Ordinary Shares · 2,575 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the Plan and the award agreement. F6 · derivative.exercise_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on the Company's total shareholder return ("TSR") for the three-year period beginning on January 1, 2024 and ending December 31, 2026 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F6 · derivative.expiration_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on the Company's total shareholder return ("TSR") for the three-year period beginning on January 1, 2024 and ending December 31, 2026 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 16:05 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 1,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000123 · wk-form4_1726603520.xml · derivative · entry 3 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,287 Underlying: Ordinary Shares · 1,287 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the Plan and the award agreement. F5 · derivative.exercise_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's Return on Investment Capital ("ROIC") calculated for the performance period 2024-2026 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F5 · derivative.expiration_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's Return on Investment Capital ("ROIC") calculated for the performance period 2024-2026 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 16:05 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 1,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000123 · wk-form4_1726603520.xml · derivative · entry 2 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,287 Underlying: Ordinary Shares · 1,287 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Company, GBP 1.00 par value, in accordance with the terms of the Plan and the award agreement. F4 · derivative.exercise_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's free cash flow ("FCF") for performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F4 · derivative.expiration_date: On September 15, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's free cash flow ("FCF") for performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 16:05 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000123 · wk-form4_1726603520.xml · derivative · entry 1 Poletti Franco · CIK 0002031281 · President, Cardiopulmonary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Underlying: Ordinary Shares · 2,575 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of LivaNova PLC (the "Company"), GBP 1.00 par value, in accordance with the terms of the Company's 2022 Incentive Award Plan (the "Plan") and the award agreement. F2 · derivative.exercise_date: On September 15, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting occurring on September 15, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. F2 · derivative.expiration_date: On September 15, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting occurring on September 15, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.